Author + information
- Received September 9, 1992
- Revision received January 27, 1993
- Accepted February 4, 1993
- Published online August 1, 1993.
- Ian T. Meredith, MBBS, PhD∗,1,1,
- Jeffery F. Alison, MBBS1,
- Fu-Min Zhang, MBBS1,
- John D. Horowitz, MBBS, PhD° and
- Richard W. Harper, MBBS, FACC1
- ↵∗Present address and address for correspondence: Ian T. Meredith, MBBS, PhD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115.
Objectives. This study was designed to examine the effects of captopril on the coronary vascular response to nitroglycerin.
Background. The vasodilator effects of nitroglycerin are mediated by sulfhydryl-dependent bioconversion and influenced by local and systemic neural and hormonal counter-regulatory factors.
Methods. In patients with angina pectoris, the effects of 10 days of treatment with the sulfhydryl-containing angiotensin-converting enzyme inhibitor captopril on the coronary vasodilator responses to intracoronary (1- to 20-μg doses) were examined utilizing a double-blind, placebo-controlled, randomized design. The effects of captopril on the induction of nitroglycerin tolerance were also examined after a 20-h intravenous infusion of nitroglycerin.
Results. Captopril reduced mean arterial pressure at rest by 8 mm Hg compared with 3 mm Hg in the placebo group (p = NS) and did not affect baseline coronary blood flow (168 vs. 144 ml/min in the placebo group, standard error of the differences of means (SED) 26) or coronary vascular resistance (53 vs. 57 dynes · s · cm−5, SED 9).Intracoronary nitroglycerin increased coronary blood flow in a dose-dependent fashion in both the captopril and placebo groups (p < 0.001). However, captopril potentiated the effects of all doses of nitroglycerin and shifted the dose-response relationship to the left (p < 0.001). At the maximal dose of 20 μg, intracoronary nitroglycerin increased the coronary blood flow by a further 60% in the captopril group with placebo. After 20 h of intravenous nitroglycerin (24 ± 3 μg/min), the coronary vasodilator responses to intracoronary nitroglycerin were attenuated (p < 0.02) in the placebo group. However, the responses to intracoronary nitroglycerin in the captopril group, remained similar to the responses observed intravenous nitroglycerin exposure.
Conclusions. Captopril potentiates the coronary vasodilator responses of nitroglycerin in both the absence and the presence of nitroglycerin tolerance. The mechanisms and theraputic implications of this interaction require further exploration.
- Received September 9, 1992.
- Revision received January 27, 1993.
- Accepted February 4, 1993.